Tag: Sirturo

As the first new drug developed specifically for tuberculosis in over 40 years, bedaquiline represents a significant advancement in treating drug-resistant strains. While most patients are familiar with its oral tablet form, Sirturo, few understand its origin as bedaquiline BDQ drug powder—the critical active pharmaceutical ingredient (API) that must first be synthesized and purified before it can be formulated into a medicine. This review explores the nature of this essential raw material and its journey to becoming a potent clinical tool.

As of 2024, approximately half a million people globally are estimated to become ill with multidrug-resistant or rifampicin-resistant tuberculosis annually. This public health crisis has made the development of novel treatments critical, leading to the introduction of BDQ, or bedaquiline, a medication used to combat these stubborn infections.